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(15.5% approvals) and highest in 2006 (39.5%) but there was no clear trend over
time. Ophthalmology MDs (6 MDs with 7 approvals) primarily focused on symp-
toms, vision-related functioning and satisfaction. Only two used validated PRO-
instruments. In the EU, PRO endpoints were used in clinical trials for three of
the six ophthalmology MDs, and included symptoms, functioning and
health-related-quality-of-life. CONCLUSIONS: Discrepancies in the transparency
of the US/EU MD-approval process render comparative research impossible. How-
ever, PROs do not appear to be widely used in the assessment of MDs, particularly
in the EU. This is a missed opportunity to capture the patient-perspective on effi-
cacy and acceptability of MDs.
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Traditionally, the reporting of adverse drug reactions (ADRs) by health care profes-
sionals is recognized well. In the recent decades, the significance of consumer
reporting of ADRs have been give due attention in the developed nations. There are
documented reasons on the failure of health care professionals in reporting ADRs
communicated by the patients. OBJECTIVES: The present study aimed to evaluate
and compare the Pharmacovigilance systems in 70 different countries with regards
to consumer reporting of ADRs. METHODS: The official websites of regulatory/
medicines agencies or National Pharmacovigilance Centres of selected 70 coun-
tries, which joined the World Health Organization’s (WHO) International Drug
Monitoring Program between 1968 and 2010, were evaluated. RESULTS: In most of
the countries, health care professionals are legally obliged to report ADRs to the re-
spective medicines authorities. Only 17 countries (24.3%) accept ADR reports directly
from consumers. Of them, only 4 countries (5.7%) accept consumer reports by phone
and 11 countries (15.7%) have a web-based electronic system for consumer reporting.
CONCLUSIONS: The consumers report relatively untapped suspected reactions for
many prescription and non-prescription drugs. Recent literature from these countries
strongly stressed the WHO’s view in successful use of consumers as one of the valu-
able source of drug safety data. It is high time that the consumer reporting should be
encouraged in all the countries, especially the developing nations, for better drug
surveillance. Proper educational interventions are required to the general public to-
wards active involvement in the respective National Pharmacovigilance Programs,
which in turn improves the quality use of medicines.
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OBJECTIVES: Despite the increasing attention for active patient participation in
health care policy decisions, systematic use of the available evidence on collective
patient preferences (passive patient participation) is still limited. Objective of this
study is 1) explore opinions and ideas regarding the use of evidence on patient
preferences in coverage decisions and clinical practice guideline (CPG); 2) describe
how and what type of evidence on patient preferences is considered in health care
policy decisions in 5 European countries. METHODS: A literature search was per-
formed to identify opinion papers on patient preferences in the context of CPG or
coverage decisions. A document search was performed on websites and databases
of the responsible organisations of the Netherlands, England, Scotland, Germany
and France. Furthermore, a few coverage decisions and CPG were checked on the
subject. RESULTS: The debate on the integration of evidence on patient prefer-
ences concerns the definition and terminology of preferences, the question
whether patient or public values should be used for policy-making, the different
methods, quality and evidence synthesis of research on patient preferences, the
relevance of including patient preferences, and the discussion on outcomes be-
yond the QALY. The procedures for coverage decisions do not mention the search
for or use of evidence on patient preferences, nor was information found in the
coverage decisions. Only in the Scottish CPG procedure a literature search on pa-
tient evidence (not necessarily patient preferences) is obligatory prior to the first
meeting. In the Netherlands this is optional. Only the selected CPG from Nether-
lands, England and Scotland mention the use of information on patient prefer-
ences in different conceptualisations. CONCLUSIONS: In coverage decisions evi-
dence on patient preferences has no formal role yet. In CPG this role is limited.
Several issues and possible barriers are under debate regarding in the integration of
evidence on patient preferences in health care policy decision-making.
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OBJECTIVES:Drug non-adherence is associated with significant negative economic
and public health burdens. The objective is to contribute to the literature on neg-
ative monetary incentives (i.e., penalties) by developing a discourse for an innova-
tive approach that could be validated in further experimental studies.METHODS:A
comprehensive database search (PubMed, EconLit) was conducted on economic
incentive programs to enhance adherence in drug therapy. Criteria for evaluation
of the retrieved economic studies have been taken from the literature. RESULTS:
Little evidence explicitly dealing with economic incentives in the form of monetary
sanctions in order to improve adherence or compliance was retrieved from the
literature search. Ethics legitimate incentive-based health care designs including
penalties if elements such as the standard of knowledge, social awareness, and
individual responsibility are well addressed and outweigh any profit orientation.
Transaction costs remain the main barrier in both institutional implementation
and practical enforcement of contractual monitoring and settlement of penalties.
Hence, a multifaceted approach would be necessary to present a sustainable con-
cept fulfilling the aspects of equal access to health care, social equity, and eco-
nomic viability. CONCLUSIONS: Financial penalties for drug non-adherence are
still a long way off as the concept lacks a simple solution. This paper contributes to
the widespread discussion by concentrating and aggregating widely scattered fig-
ures of dispute within a coherent argumentative discourse drawing on insights
from the field of health economics.
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OBJECTIVES: The first real independence makes student population exposed to
various health risks. The aim of this study was to examine the health of students
and their using of health care services and medicines. METHODS: The cross-sec-
tional study was carried out at the three State Universities from February to May in
the academic year 2011/2012. and included 2285 students of both sexes. The stu-
dents filled in a questionnaire consisting of 30 questions referring to socio-eco-
nomic characteristics, life-style habits, health assessment, as well as some health
problems and use of health services. RESULTS: Half of all students reported having
a selected physician. Of the total number of students 59.8% of them had been to the
doctor and 63.8% of students used the services of a dentist at least once in the year
preceding the survey. As the most common reasons for visiting general practitio-
ners, students cited the control of health and medical examinations (40.4%), the
existence of an illness or injury (32.1%), as well as instructions for obtaining a
specialist (11.7%). The average number of physician visit per student was 1.89 (SD
2.81) and the number of actual dental visit per student was 2.33 (SD 3.93). Of the
total number 77.2% of students had never been hospitalized. Most students taking
the medication on the advice of doctors (49.1%). Medication is not used at all for
24.2% of students. Cochran’s Q test showed a statistically significant difference
between groups of drugs which the students took on their own initiative, where the
first stand pain medication, and then the drugs to strengthen the body (p 0.001).
CONCLUSIONS: Universities should be encouraged to provide efficient, affordable
counseling services for their students. Students must be encouraged to become
actively involved in health promotion.
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OBJECTIVES: The use of antibiotics is found to be irrational by patients as well as
prescribers and lack of knowledge and information about the adverse effects and
the increasing prevalence of resistant organisms are some of the important factors
which caused it. So national education programs about the dangers of irrational
antibiotic use should be the priority. Affecting on these ideas in adults takes too
much time and money, but education is more effective in children and its effect on
a child becomes fixed in their beliefs. This study aimed to assess and compare the
effectiveness of wallpaper news and story book designed to teach children about
the benefits of appropriate use of antibiotics. METHODS: The children story book
and wallpaper news which have been designed and published by National Com-
mittee on Rational Use of Drug (NCRUD) were delivered to 18 primary school (9 for
girls and 9 for boys) that volunteered to participate in the study in Tehran. All
student of third, fourth and fifth grade have been educated by their trained teach-
ers. The evaluation of children’s Knowledge has been done on all of students before
and after intervention. RESULTS: The research results found that there was signif-
icant difference between the student knowledge before and after both interven-
tions in girls’ and boys’ primary schools. (p0.0001) and the effectiveness of wall
news paper is more than story book in girls’ primary school. (p0.006).
CONCLUSIONS: We conclude that children stories have good impression on the
level of student’s knowledge and it seems that teaching the students about the
advantages of appropriate antibiotic use by using children stories can influence
their knowledge significantly and its good way to increase their level of knowledge
and positive behavior in future life.
HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group
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OBJECTIVES:To consider how reimbursement systems in 5 EU countries encourage
or inhibit adoption of medical device technologies that facilitate care in an ambu-
latory setting. METHODS: A literature review of payment systems for medical de-
vices operating in England, Germany, Italy, France and Spain was undertaken.
Examples of technologies that could be used in an out-patient setting, but which
were predominantly being used in hospital were identified. Uterine balloon endo-
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metrial ablation, low intensity pulsed ultrasound (LIPUS) and negative pressure
wound therapy were investigated further, through interviews with country and
product experts. RESULTS: Hospital and ambulatory sales could not be separated
but some differences in total sales between countries were apparent. Where HTA
processes existed they appeared to slow down access to new technologies. Several
interviewees highlighted a lack of expertise on local purchasing groups where
decisions are often based upon in-year budget considerations which restrict access
to some cost effective technologies. Even where new technologies are found to be
cost effective, DRG based funding systems are insufficiently flexible to establish
new out-patient fee levels. Hospitals have no financial incentive to treat patients in
an out-patient setting if the procedure cost exceeds existing out-patient DRG fees.
This prevents innovative technologies from being used in the most appropriate
way and cost saving opportunities are missed. CONCLUSIONS: Health providers
need to demonstrate new technologies are cost effective before commissioners
agree funding outside DRG based fee systems. The negotiation process would be
more efficient if commissioners pooled expertise for reviewing cost-effectiveness
evidence and fed their conclusions directly to DRG code and Tariff setting author-
ities. New DRG codes and higher out-patient tariffs for cost effective technologies
that enable a switch to ambulatory care could incentivise hospitals to revise care
pathways. Benefits will include lower procedure costs than in-patient treatment or
improved outcomes for patients.
HEALTH CARE USE & POLICY STUDIES - Disease Management
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OBJECTIVES: An increasingly high-profile policy initiative being driven by the De-
partment of Health (DoH), the Association of the British Pharmaceutical Industry
(ABPI) and National Health Service (NHS) stakeholders, “joint working” encom-
passes a variety of forms of collaboration between the industry and the NHS in the
UK (UK). This study sought to characterise the current landscape for joint working
in the UK by surveying the types of projects being undertaken by participants.
METHODS: Secondary research was conducted to establish a comprehensive list of
joint-working projects; the websites of major pharmaceutical companies, the ABPI,
the DoH and other NHS stakeholders were surveyed for any references to joint
working. A classification system was created to segment projects by type of
scheme, therapeutic area(s) and stakeholders involved. This segmentation was
analysed to look for qualitative trends in the UK joint-working environment.
RESULTS: A key finding of the study is that many pharmaceutical companies are
now active in joint working. Joint-working projects encompass a broad range of
therapeutic areas, with most companies active in areas in which they have assets.
These projects can be segmented into a number of different categories, including
those centered on service (re)design, service appraisals in light of current guide-
lines, and techniques to better manage or educate patients. Pharmaceutical com-
panies are also active in providing training or other types of support to health care
professionals and managers within the NHS. CONCLUSIONS: The joint-working
policy initiative in the UK has resulted in a significant number of partnerships
within the NHS in recent years. These projects are varied in nature, and have seen
the pharmaceutical industry and the health service cooperate in innovative ways.
Increasingly, companies are willing to share their expertise and resources in proj-
ects which have indirect benefits for them in terms of the market access of their
products.
HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy
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OBJECTIVES: To compare and explain current drug pricing systems in Bosnia and
Herzegovina (B&H) for reimbursed drugs by Health Insurance Funds (HIF) and out-
of-pocket drugs. METHODS: Analysis of reimbursement list and legislation on ac-
ces to drugs in B&H is performed. We analysed pricing for reimbursed drugs and
out-of-pocket drug prices regulation and explain cost structure. RESULTS: General
drug pricing system is set by Agency for medicines and medical devices of B&H.
Prices are defined as maximal wholeseler price (WSP) and pricing is based on re-
feral pricing. Referal countries are Croatia, Serbia, Slovenia, Austria and Italy. B&H
price must be set at level of referal price with addoption for patented drug (100%),
originator (95%) and generics (90%). Prices are revised each year and published on
Agency website. Maximal wholeseler margine is up to 8%, while retail margine is
set by entity laws. In Federation maximal retail margine is 25% while in Republic of
Srpska margine is fixed on 20% add on WSP. Reimbursable price in Republic of
Srpska is defined as lowest offered price for each INN and presentation. Price dif-
ference can be paid by patient depenting on preferences. Reimbursed prices for
drugs included into Federal reimbursement list is set by nagotiation process with
manufacturers. All prices should be revised and adopted annualy to the Agency
published prices. Retail margine is not applicable for reimbursed drugs because
pharmacy is paid by HIF per prescription according to the agreement.
CONCLUSIONS: Even there is intention to unify pharmaceutical market and drug
prices in Bosnia and Herzegovine, there are still differences in price and related
pricing regulations. Recently published Rule on price control by state Agency
should contribute to equalisation of prices in Bosnia and Herzegovina.
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OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the annual turnover of community pharmacies. METHODS: Data were derived
from the pharmaceutical database of the Hungarian Health Insurance Fund Ad-
ministration (OEP), the only health care financing agency in Hungary. We analysed
the 5 years period between 2006-2010. The main indicator of our analyses was the
annual turnover of pharmacies calculated on health insurance reimbursement
according to the number of population of different settlements. RESULTS: The
average annual turnover – calculated on health insurance reimbursement – of a
community pharmacy was 176.8 million Hungarian Forint (HUF) or 669011 EUR in
2006 with significant differences according to the size of population. Pharmacies
located in small cities had a much lower average annual turnover (0-499 popula-
tion: 105.6 million HUF; 500-999: 41.9 million HUF; 1000-1999: 63.2 million HUF),
while the turnover of pharmacies located in bigger cities, was significantly higher
(10000-49999 population: 217.6 million HUF; 50000-99999: 231.9 million HUF; over
100000: 241.6 million HUF). The average annual turnover of a community pharmacy
was 135.4 million Hungarian Forint (HUF) or 491627 EUR in 2010, i.e. 76.6 % of 2006’s
turnover. Between 2006 and 2010, the annual turnover of pharmacies in small
villages (population 0-1999) varied between 86.1-103.7 % while those of big cities
(population over 10000) changed to 66.9-76.5 %. CONCLUSIONS: The annual turn-
over of pharmacies in small villages was significantly lower than those of big towns
during the study period 2006-2010. However, the annual turnover of small villages’
pharmacies decreased moderately compared to pharmacies located in bigger
towns because new pharmacies were established in bigger towns.
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OBJECTIVES: In an attempt to assess time to market and price levels of innovative
drugs, we surveyed market availability and drug prices for a basket of drugs in the
top 5 European pharmaceutical markets.METHODS: The market availability of 125
innovative drugs – approved between July 2009 and April 2012 by the European
Medicines Agency – in France, Germany, Italy, Spain, and the United-Kingdom was
analysed. Within this sample, prices of 10 drugs marketed in each of the market
studied were compared. RESULTS: Most of the drugs included in our sample are
marketed in Germany and the UK, 59% and 54% respectively. In Spain, France and
Italy this figure drops to 39%, 33%, and 32% respectively. It should be highlighted
that only 14% of the drugs was available in all the markets analysed. Prices are
commonly the highest in Germany and lower in Italy or the UK. Additionally, while
for an identical drug, most examples show significant price differences between
the markets studied, a few showed that the price corridor was relatively narrow.
CONCLUSIONS:Our results show that Germany and the UK – where prices have not
been directly controlled – are still prioritised, while market entry occurs at a later
stage in France, Italy and Spain. The fact that large price differences are still ob-
served between countries means that there is still flexibility in terms of pricing
strategies. The pricing procedure implemented in 2011 in Germany, has not had an
immediate impact on prices - which are still the highest. However, an impact is
already being felt on market access. Several innovative drugs were not launched in
Germany when the price outcome was expected to be unsuccessful.
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OBJECTIVES: Drug manufacturers, facing patent protection termination, have de-
veloped strategies to maintain market share. These include marketing evergreen-
ing drugs (slow release formulations, single isomer chiral molecules, or structural
analogues/combinations of original patented drugs) and offering high rebates to
hospitals that use brand-name or evergreening drugs. Our objective was to assess
the financial impact of evergreening drug prescriptions in the community, and to
measure the impact of a hospital restrictive drug formulary (RDF) on health care
expenditures. METHODS: We combined three administrative registries from the
canton of Geneva, Switzerland to analyse all prescriptions between January 2000
and December 2008. We developed cost-minimisation models calculating ever-
greening and brand drug prescriptions at their corresponding generic selling price
equivalents. ARIMA models measured the spillover effect of hospital prescription
patterns into the community. Spillover costs were compared to hospital savings.
Summary results were aggregated on a yearly basis and extrapolated to the canton
of Geneva. RESULTS: Evergreening drug prescriptions resulted in an extra cost of
€20,172,000 over the study period. Brand drug extra costs decreased from €6,555,000
(2004) to €1,403,000 (2008), but were offset by the increase in evergreening drug
prescriptions (“squeezing the balloon” phenomenon). The final extra cost to the
health care system was €42,147,000. The use of a hospital RDF to control cost
resulted in global savings of €837,000. However, listing drugs on the hospital RDF
decreased health care system savings to €31,000 only due to increased prescription
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